Azenta sells B Medical Systems to related-party Thelema for $63M; close by Mar 31, 2026

Azenta, Inc.

Sale of B Medical Systems subsidiary to Thelema S.À R.L. for USD 63M; Thelema is majority-owned by Azenta VP & B Medical CEO Luc Provost.
Thelema deposited $9M; remaining $54M due on or before Mar 31, 2026, subject to securing final residual financing.
If financing condition not satisfied by Mar 31, 2026, Azenta retains $5M break-up fee and may terminate.
Proceeds to be deployed to strengthen company and drive long-term shareholder value, per CEO John Marotta.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Azenta, Inc. entered into Share Purchase Agreement with Thelema S.À R.L. valued at USD 63,000,000 (effective 2025-12-23).

Action: entry
Agreement: asset purchase
Counterparty: Thelema S.À R.L.
Value: USD 63,000,000
Effective: 2025-12-23

Exact text from the filing

On December 23, 2025, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Sale and Purchase Agreement (“Share Purchase Agreement”) with Thelema S.À R.L. (“Thelema”) relating to the entire issued share capital of B Medical Systems S.À R.L. (“B Medical”), a subsidiary of Azenta Germany GmbH.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-038787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.